2024
Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial. Journal Of Substance Use And Addiction Treatment 2024, 164: 209438. PMID: 38857827, PMCID: PMC11300157, DOI: 10.1016/j.josat.2024.209438.Peer-Reviewed Original ResearchXR-NTXBuprenorphine-naloxoneOpioid use disorderCriminal legal involvementUse disorderHazard of overdoseLifetime incarcerationLegal involvementOpioid use disorder treatment outcomesPer-protocol analysisExtended-release naltrexoneMOUD effectivenessTreatment outcomesEffects of medicationHazard of relapseSecondary analysisIntention-to-treat analysisIntention-to-treatRandomized controlled trialsEffects of MOUDRelapseControlled trialsDisordersOpioidPotential effect modifiers
2019
Medications for Opioid Use Disorder Among Incarcerated Individuals: a Review of the Literature and Focus on Patient Preference
Puglisi L, Bedell P, Steiner A, Wang E. Medications for Opioid Use Disorder Among Incarcerated Individuals: a Review of the Literature and Focus on Patient Preference. Current Addiction Reports 2019, 6: 365-373. DOI: 10.1007/s40429-019-00283-x.Peer-Reviewed Original ResearchPatient preferencesMOUD treatmentUse disordersEffectiveness studiesOpioid use disorderChronic health conditionsNeed-based factorsPatient-centered researchCommon diagnosisPatients' perceptionsTreatment utilizationTreatment decisionsMOUDTreatment engagementIncarcerated peopleHealth needsMedicationsStudy designHealth conditionsVulnerable populationsTreatmentDisordersIncarcerated individualsFuture studiesCorrectional populations